236 POSTER Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D cohort
A. Townsend, P. Padrik, P. Mainwaring, T. Price, L. Catley, A. Longenecker, M.A. Palladino, G.K. Lloyd, M.A. Spear, M. MillwardVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72168-2
File:
PDF, 59 KB
english, 2008